Institutional Repository of Vilnius University
Pridėtinės vertės mokesčio lengvatinio tarifo taikymo analizė vaistams Lietuvoje /
Abstract
dc:descriptionAnalysis of Reduced Value Added Tax Rate Application for the Pharmaceutical Products in Lithuania As the value added tax is one of the main taxes it is a popular subject of discussion. Some authors emphasize the positive effect of this indirect tax, while others raise their disadvantages. One of the most often highlighted disadvantage is a regressive value added tax feature. To solve this problem many countries start using reduced value added tax rates. One of these products is pharmaceutical products that have a significant impact on such important factors as population health, life expectancy, etc. However, the effectiveness and impact of value added tax on pharmaceutical products are poorly discussed. Therefore, I decided to take a closer look at this area and make sure that regulating pharmaceutical products prices with the use of VAT reductions is effective. Aim of the work is to analyze the dependence of the value added tax for pharmaceutical products and the relationship with consumers, consumption and the state budget. The purpose of this study is to analyze the main aspects of the application of the exemption to medicinal products. Several research methods are used in the written work. To reach a goal, I did a documentary study of secondary information related to the research as an analysis of tax-related global scientific literature, overview and analysis of European Union and Lithuanian statistics, legislation and studies. The collected information was grouped, compared and evaluated and summarized. Financial data analysis, regression and correlation analysis were used to check the dependence of the value added tax relief on pharmaceutical products and the relationship with consumption and state budget. By the way, I took induction method by comparing changes in prices for certain medicines in 2017-2018. To sum up, the value added tax reduced rate on pharmaceutical products improves the availability of medicines and reduces costs, but this is not enough to sufficiently ensure social justice. In order to achieve the desired effect, there have to be used other regulators with value added tax reduced rate. To improve effectiveness there can be used better control of set requirements for pharmaceutical products trade in order to avoid unauthorized effects on manufacturers and pharmacists, to more effectively inform patients of the choice of cheaper analogues of medicines and to promote the market entry of cheaper medicines and competition between them.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Markevič, Diana,
Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- lit
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD193299299&prefLang=en_US